SEARCH

SEARCH BY CITATION

References

  • 1
    Meineche-Schmidt V, Jorgensen T. Fluctuation in dyspepsia subgroups over time. A three-year follow-up of patients consulting general practice for dyspepsia. Dig Liver Dis 2002; 34: 3328.
  • 2
    Lundquist P, Seensalu R, Linden B, Nilsson LH, Lindberg G. Symptom criteria do not distinguish between functional and organic dyspepsia. Eur J Surg 1998; 164: 34552.
  • 3
    Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 208.
  • 4
    Talley NJ. Therapeutic options in nonulcer dyspepsia. J Clin Gastroenterol 2001; 32: 28693.
  • 5
    Giger M, Brignoli R. Oberbauchbeschwerden und deren Einfluss auf Lebensqualität und Konsum von medizinischen Leistungen [Prevalence of upper abdominal complaints and their effect on the quality of life and utilization of medical resources. Swiss Primary Care Group]. Schweiz Med Wochenschr 1998; 128: 8749.
  • 6
    Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 2937.
  • 7
    Stanghellini V, De Ponti F, De Giorgio R, Barbara G, Tosetti C, Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs 2003; 63: 86992.
  • 8
    Bazaldua OV, Schneider FD. Evaluation and management of dyspepsia. Am Fam Physician 1999; 60: 177384, 1787–8.
  • 9
    Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003(1); CD001960.
  • 10
    Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001; 96: 1698703.
    Direct Link:
  • 11
    Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003(1); CD002096.
  • 12
    Saller R, Iten F, Reichling J. Dyspeptische Beschwerden und Phytotherapie - eine Übersicht über traditionelle und moderne Phytotherapeutika [Dyspeptic pain and phytotherapy – a review of traditional and modern herbal drugs]. Forsch Komplementarmed Klass Naturheilkd 2001; 8: 26373.
  • 13
    Thompson Coon J, Ernst E. Systematic review: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002; 16: 168999.
  • 14
    Reichling J, Saller R. Iberis amara L. (Bittere Schleifenblume) – Profil einer Heilpflanze [Iberis amara L. (bitter candytuft) – profile of a medicinal plant]. Forsch Komplementarmed Klass Naturheilkd 2002; 9 (Suppl. 1): 2133.
  • 15
    ESCOP. European Scientific Cooperative on Phytotherapy Monographs. 2nd edn. Stuttgart, Germany: Thieme, 2003.
  • 16
    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61: 203563.
  • 17
    Willuhn G. Angelica root. In: WichtlM, eds. Herbal Drugs and Phytopharmaceuticals. Stuttgart, Germany: Medpharm Scientific Publisher, 2004: 3841.
  • 18
    Saller R, Pfister-Hotz G, Iten F, Melzer J, Reichling J. Iberogast: Eine moderne phytotherapeutische Arzneimittelkombination zur Behandlung funktioneller Erkrankungen des Magen-Darm-Trakts (Dyspepsie, Colon irritabile) – von der Pflanzenheilkunde zur ‘Evidence based Phytotherapy’: Eine systematische Übersicht [Iberogast: a modern phytotherapeutic combined herbal drug for the treatment of functional disorders of the gastrointestinal tract (dyspepsia, irritable bowel syndrome) – from phytomedicine to ‘evidence based phytotherapy’. A systematic review]. Forsch Komplementarmed Klass Naturheilkd 2002; 9 (Suppl. 1): 120.
  • 19
    MacLean CH, Morton SC, Ofman JJ, Roth EA, Shekelle PG. How useful are unpublished data from the Food and Drug Administration in meta-analysis? J Clin Epidemiol 2003; 56: 4451.
  • 20
    Mulrow CD, Oxman AD. Cochrane Collaboration Handbook. Update Software: The Cochrane Collaboration, 1996.
  • 21
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. 2): II3742.
  • 22
    Stanghellini V, Tosetti C, Paternico A, et al. Predominant symptoms identify different subgroups in functional dyspepsia. Am J Gastroenterol 1999; 94: 20805.
    Direct Link:
  • 23
    ESCOP. Software RevMan and RevMan Manual, 3rd edn. NCC: Monica Fischer, 1996.
  • 24
    Holtmann G, Madisch A, Hotz J, et al. A double-blind, randomized, placebo-controlled trial on the effects of a herbal preparation in patients with functional dyspepsia. Gastroenterology 1999; 116: A65 (Abstract).
  • 25
    Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion 2004; 69: 4552.
  • 26
    Sassin I, Buchert D. Efficacy and tolerability of the herbal preparation Iberogast in the therapy of functional dyspepsia. Phytomedicine 2000; 7 (Suppl.): 912.
  • 27
    Nicolay K. Funktionelle Gastroenteropathien im therapeutischen Blindvergleich von Metoclopramid mit dem Phytotherapeutikon Iberogast. Gastro-Entero-Hepatologie 1984; 2: 112.
  • 28
    Buchert D. Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie (Abstracts): 5. Phytotherapiekongress, Bonn, 1993. Zeitschrift für Phytotherapie 1994; 15: 24, 27.
  • 29
    Schnitker J, Schulte-Körne C. Integrierter Abschlussbericht PFK CR-III-003-94 G Biometrischer Teil. Bielefeld: Institut für angewandte Statistik, Schnitker GmbH, 1999, Report No. 1.
  • 30
    Madisch A, Melderis H, Mayr G, Sassin I, Hotz J. A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study. Z Gastroenterol 2001; 39: 5117.
  • 31
    Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40: 4018.
  • 32
    Bailar JC. The promise and problems of meta-analysis. N Engl J Med 1997; 337: 55961.
  • 33
    Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 2002; 21: 37187.
  • 34
    Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 105565.
  • 35
    Greving I, Meister V, Monnerjahn C, Muller KM, May B. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Saf 1998; 7: S669.
  • 36
    Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by greater celandine (Chelidonium majus). Gastroenterology 1999; 117: 12347.
  • 37
    Freise J, Kohler S. Peppermint oil-caraway oil fixed combination in non-ulcer dyspepsia – comparison of the effects of enteric preparations. Pharmazie 1999; 54: 2105.
  • 38
    May B, Kohler S, Schneider B. Efficacy and tolerability of a fixed combination of peppermint oil and caraway oil in patients suffering from functional dyspepsia. Aliment Pharmacol Ther 2000; 14: 16717.
  • 39
    Stadelmann O, Köhler S, Kieser M, Stolte M. Pfefferminzöl/Ingwerextrakt bei funktioneller Dyspepsie. Randomisierte plazebo-kontrollierte Wirksamkeits- und Verträglichkeitsstudie mit Kombinationspräparat. Leber Magen Darm 1999; 29 (Suppl. 2): 18.